Development of Quinoline‐Isoxazole Hybrids With Selective Cytotoxicity and EGFR Kinase Binding: In Vitro and In Silico Approaches
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70219 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Yasemin Zeynep Şahin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Basic Science, Gebze Technical University, Gebze, Kocaeli, Türkiye. Hauptthemen laut MEDLINE: ErbB Receptors, Quinolines, Antineoplastic Agents, Isoxazoles. Die Arbeit nennt 64 Literaturangaben. Gefördert von: Gebze Teknik Üniversitesi.
Abstract (Originalsprache)
Fourteen new quinoline‐isoxazole hybrid compounds were synthesized through click reaction with different substituent groups on the isoxazole group. The in vitro therapeutic activeness of the synthesized hybrids had been assessed versus diverse cell lines (MCF7, SKOV3, A549, LN229), using the standard tamoxifen as a reference. According to cell viability results, the most active molecules were found to be 4b against MCF7 cells (IC 50 = 12.94 μM) and compound 4f in the SKOV3 cells (IC 50 = 17.89 μM), as well as showing no cytotoxicity on the healthy human fibroblast cell line (MRC‐5). These results showed us that the new compounds were selective for cancer cell lines . As an indicator of apoptosis, a significant decrease in the level of PARP protein was observed in the MCF7 cells for 4b and in the SKOV3 cells for 4f . After analyzing PARP levels by Western blot, apoptosis levels were also investigated by flow cytometry analysis. The mechanism of the 1,3‐dipolar cycloaddition reaction between acetylene and benzaldoxime derivatives was investigated using time‐dependent density functional theory (TDDFT). The calculated HOMO–LUMO energy differences and the changes in frontier orbital distributions were found to be consistent with the experimentally observed variations in reaction yield. The molecular docking investigation was conducted to evaluate the binding affinities, interactions, and binding modes of novel hybrid compounds with a target receptor, EGFR kinase (PDB ID: 4G5J). Results showed that compounds 4e and 4f presented favorable binding energies compared to the reference molecule Afatinib. Molecular dynamics simulations confirmed the stable binding of compound 4f with EGFR, with the complex reaching equilibrium after ~20 ns and maintaining an average RMSD of 0.25 ± 0.05 nm throughout the 100 ns trajectory. In silico ADME results also show that all synthesized molecules obey Lipinski's rules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, College of Basic Science, Gebze Technical University, Gebze, Kocaeli, Türkiye.
- Research Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University, Istanbul, Türkiye.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul Medipol University, Istanbul, Türkiye.
- Department of Chemistry, Faculty of Sciences, Karadeniz Technical University, Trabzon, Türkiye.
ORCID-Profile: İrem Kulu
Förderung
- Gebze Teknik Üniversitesi
Zitieren
APA
Şahin, Y. Z., Tan, B., Hamur, B., Albayrak, F., Koc, E. B., Sucu, B. O., Kol, Ö. G., & Kulu, İ. (2025). Development of Quinoline‐Isoxazole Hybrids With Selective Cytotoxicity and EGFR Kinase Binding: In Vitro and In Silico Approaches. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70219
Vancouver
Şahin YZ, Tan B, Hamur B, Albayrak F, Koc EB, Sucu BO, et al. Development of Quinoline‐Isoxazole Hybrids With Selective Cytotoxicity and EGFR Kinase Binding: In Vitro and In Silico Approaches. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70219
BibTeX
@article{ahin2025,
author = {Şahin, Yasemin Zeynep and Tan, Burcu and Hamur, Beyza and Albayrak, Fatma and Koc, Elif Beyza and Sucu, Bilgesu Onur and Kol, Özlem Gürsoy and Kulu, İrem},
title = {Development of Quinoline‐Isoxazole Hybrids With Selective Cytotoxicity and EGFR Kinase Binding: In Vitro and In Silico Approaches},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70219}
}
EUVIMED